Whilst the overall market for Nuvaring (original and generics) appears to be shrinking, it's still a half a billion dollar plus annual market in the US. Even if Mayne took a very modest 10-20% market share, that's still $50-$100 million a year in additional revenue from one product. Separately, I wonder if Mithra/Mayne have pondered the possibility of a new and improved version of Nuvaring by substituting the plant-based estrogen from Nextstellis and creating a "natural ingredient" version of Nuvaring?
Whilst the overall market for Nuvaring (original and generics)...
Add MYX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$7.01 |
Change
0.210(3.09%) |
Mkt cap ! $596.3M | |||
| Open | High | Low | Value | Volume |
| $6.88 | $7.04 | $6.80 | $2.632M | 382.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 425 | $6.96 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $7.01 | 1245 | 1 |
View Market Depth
| Last trade - 16.10pm 02/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$7.01 |
Change
0.210 ( 3.14 %) |
||||
| Open | High | Low | Volume | ||
| $6.81 | $7.04 | $6.81 | 43609 | ||
| Last updated 15.59pm 02/05/2024 ? | |||||
| MYX (ASX) Chart |